New research is helping scientists better understand gene modification’s effects on many forms of bladder cancer. Additionally, results from numerous recent studies seem to foreshadow a change of tide in the management of many urologic cancers in the coming years.
Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22.
Collazo-Lorduy A, Galsky MD. Systemic therapy for metastatic bladder cancer in
2016 and beyond. Future Oncol. 2016;12(9):1179-92.
Oing C, Rink M, Oechsle K, et al. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195(2):254-63.
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267-79.